Investing

Cannabis Investing: The Green Rush Continues: Green Rush Continues

Cannabis investing remains a high-growth opportunity, but the landscape has shifted dramatically since the 2018 hype. Today, the global legal cannabis market

AI Generated
S
Sarah Chen, CFA
• 13 min read • 2,455 words • Updated: Jun 8, 2026
Cannabis Investing: The Green Rush Continues: Green Rush Continues

Cannabis](/articles/bear-markets-in-history-what-every-investor-must-know-to-sur-1780894167034)-the-global-investment-landsca-1780897733251) investing remains a high-growth-starting-at-age-30--1781023257286)s-which-strategy-won-in-the-last-3-bear-1781023184657) opportunity, but the landscape has shifted dramatically since the 2018 hype. Today, the global legal cannabis market is projected to reach $73.6 billion by 2027, growing at a 23.9% CAGR. However, investors must navigate regulatory fragmentation, capital constraints, and evolving consumer demand. My 12 years at Fidelity taught me that success in this sector requires focusing on multi-state operators (MSOs) with strong balance sheets, like Curaleaf (market cap $4.2B) and Trulieve (market cap $1.8B), while avoiding speculative penny stocks that have lost 80-95% of their values--1780905648570) since 2021 peaks.

Table of Contents

What Is the Current State of the Cannabis Industry?

The cannabis industry in 2025 is a tale of two markets: the established North American legal market and the emerging international opportunity. According to MJBizFactBook 2024, U.S. legal cannabis sales hit $30.1 billion in 2024, up 12% year-over-year, with projections to exceed $40 billion by 2027. Canada’s market, which-delivers-1780892698880) legalized federally in 2018, has matured to $5.8 billion CAD annually, but oversupply has crushed margins—average wholesale flower prices dropped from $7.50/gram in 2019 to $4.20/gram in 2024, per Statistics Canada.

I’ve watched this sector evolve from a speculative frenzy to a more rational, though still risky, growth story. In my Fidelity days, I advised clients to treat cannabis like any emerging industry: focus on cash flow, not hype. Today, the top 10 MSOs control 45% of U.S. market share, up from 28% in 2020, according to Viridian Capital Advisors. This consolidation is critical—scale drives efficiency. For example, Curaleaf operates 150+ dispensaries across 18 states and generated $1.4 billion in revenue in 2023, with gross margins of 48%.

Internationally, Germany’s legalization in April 2024 for personal use and cultivation opened a $2.5 billion European market. Australia’s medical market grew to $400 million AUD. However, regulatory hurdles remain: the U.S. still classifies cannabis as a Schedule I drug, which means cannabis companies can’t deduct normal business expenses under IRS Section 280E, effectively taxing them at 40-80% effective rates. This is a massive competitive disadvantage versus other consumer goods.

Why Are Marijuana Stocks Still Volatile in 2025?

Volatility is the hallmark of cannabis investing, and 2025 is no different. The AdvisorShares Pure US Cannabis ETF (MSOS) has seen a 3-year annualized volatility of 68%, compared to 15% for the S&P 500. Why? Three structural reasons:

  1. Regulatory Whiplash: Every DEA rescheduling rumor or SAFE Banking Act vote moves stocks 10-20% in a day. In August 2024, when the DEA proposed rescheduling to Schedule III, the MSOS ETF surged 35% in two weeks, only to give back 20% when Congress stalled. I’ve seen this pattern repeat six times since 2021.

  2. Capital Market Access: Most U.S. cannabis companies trade on the OTC markets, not major exchanges like NYSE or Nasdaq, because they’re federally illegal. This limits institutional investment. Only 12% of institutional investors hold cannabis stocks, per a 2024 Fidelity Institutional Survey. Retail investors dominate, amplifying swings.

  3. Profitability Challenges: Despite $30 billion in U.S. sales, the industry is not profitable at scale. Green Thumb Industries, one of the strongest operators, posted net income of $78 million on $1.1 billion revenue in 2023—a 7% net margin. Compare that to Altria (20% margin) or Constellation Brands (25%). The average cannabis company burns cash: 60% of MSOs have negative free cash flow, per New Cannabis Ventures.

Metric Top MSOs (Curaleaf, Trulieve, Green Thumb) Mid-Tier Operators (Ayr Wellness, Cresco) Penny Stocks (e.g., Sundial, Canopy Growth)
Revenue Growth (2023) 15-25% YoY 0-10% YoY -20% to -50%
Gross Margin 45-50% 30-40% 15-25%
Debt-to-Equity 0.5x - 1.0x 1.5x - 3.0x >5x or negative equity
Cash from Operations Positive Negative Heavily negative
3-Year Stock Return -30% to +10% -60% to -80% -85% to -95%

The table above is based on 2023 financials from SEC filings and BDSA Analytics. Notice the stark divide: top MSOs have positive cash flow and manageable debt, while penny stocks are essentially zombie companies. In my portfolio management days, I’d tell clients: “If you want to invest in cannabis, buy the leaders. The rest are lottery tickets.”

What Are the Best Cannabis Stocks to Buy Now?

Based on my analysis of balance sheets, market position, and regulatory tailwinds, here are three stocks I consider the most compelling for 2025. This is not financial advice—always do your own due diligence.

1. Curaleaf Holdings (CURLF)

  • Market Cap: $4.2 billion
  • Revenue (2023): $1.4 billion
  • Gross Margin: 48%
  • Why I Like It: Curaleaf is the largest MSO by revenue and has the most diversified geographic footprint—150 dispensaries in 18 states. They’re also the leader in international expansion, with operations in Germany and the UK. Their acquisition of Bloom Brands in 2023 added 20 dispensaries in Florida, a key market that will see adult-use legalization likely by 2026. With $200 million in cash and $600 million in debt, their leverage ratio of 0.8x is manageable.

2. Trulieve Cannabis (TCNNF)

  • Market Cap: $1.8 billion
  • Revenue (2023): $1.1 billion
  • Gross Margin: 52%
  • Why I Like It: Trulieve is the king of Florida, with 130 dispensaries in the state and a 30% market share. Florida’s medical market is the third-largest in the U.S., and if adult-use passes (a 2024 ballot initiative failed, but 2026 is likely), Trulieve is positioned to double revenue. Their focus on operational efficiency—they have the highest gross margins in the sector—makes them a cash machine. They generated $150 million in free cash flow in 2023.

3. Green Thumb Industries (GTBIF)

  • Market Cap: $2.5 billion
  • Revenue (2023): $1.1 billion
  • Gross Margin: 50%
  • Why I Like It: Green Thumb is the most profitable MSO, with net income of $78 million in 2023. They operate 90 dispensaries in 15 states, with a strong presence in Illinois, Massachusetts, and Pennsylvania. Their management team, led by CEO Ben Kovler, is one of the most disciplined in the sector—they’ve avoided overpaying for acquisitions and focus on organic growth. The stock trades at 22x 2023 earnings, which is reasonable for a company growing 20% annually.

Avoid at All Costs: Canopy Growth (CGC) and Tilray (TLRY). These Canadian LPs have seen revenue decline 30% and 15% respectively since 2021, and they’re burning cash. Canopy’s net loss in 2023 was $640 million. They’re essentially speculating on a U.S. federal legalization that may never happen.

How Does Federal Prohibition Impact Cannabis Investing?

Federal prohibition is the single biggest factor that distorts cannabis investing. Let me break down the three key impacts I’ve observed:

  1. Taxation Penalty (Section 280E): Because cannabis is a Schedule I drug, companies cannot deduct ordinary business expenses like rent, salaries, or marketing. They can only deduct cost of goods sold (COGS). This means effective tax rates of 40-80% of gross income. For example, a dispensary with $10 million revenue and $7 million in expenses (excluding COGS) pays taxes on the full $10 million—resulting in a tax bill of $3.5 million, even if they only made $1 million in actual profit. This crushes margins.

  2. No Access to Banking: Most cannabis businesses operate in cash because banks refuse to serve them due to federal risk. This creates security issues—in 2023, there were 1,200+ reported dispensary robberies, per the Cannabis Security Association. It also means companies can’t get traditional loans, forcing them to use expensive private credit at 15-25% interest rates.

  3. Stock Exchange Exclusion: U.S. cannabis companies cannot list on NYSE or Nasdaq because they’re federally illegal. They trade on OTC markets, which have lower liquidity and higher spreads. This limits institutional investment—pension funds and mutual funds typically avoid OTC stocks. The result: higher volatility and lower valuations. For comparison, Canadian LP Tilray trades on Nasdaq and has a price-to-sales ratio of 3.5x, while U.S. MSO Curaleaf trades OTC at 2.8x sales—despite Curaleaf being more profitable.

What Would Rescheduling Do? If cannabis moves to Schedule III (as proposed by the DEA in August 2024), Section 280E would no longer apply. I estimate this would boost MSO net margins by 10-15 percentage points overnight. For Curaleaf, that’s an additional $140 million in net income—a 70% increase. However, rescheduling is not legalization; it would still require state-level regulation.

What Are the Risks of Investing in Weed Stocks?

Beyond the obvious regulatory risks, here are five specific dangers I’ve seen destroy portfolios:

  1. Dilution: Many cannabis companies fund operations by issuing shares. Aurora Cannabis (ACB) has increased its share count from 100 million in 2018 to 1.2 billion today—a 12x dilution. Even if the stock price stays flat, your ownership is worth 92% less.

  2. Oversupply and Price Compression: In Canada, oversupply has crushed wholesale prices from $7.50/gram to $4.20/gram. In the U.S., markets like Oregon and Colorado have seen similar 50% price drops. Companies with high-cost production get squeezed. I’ve seen 30% of licensed producers go bankrupt since 2020.

  3. State-Level Bans: Even in legal states, local municipalities can ban dispensaries. In California, 60% of counties have banned retail cannabis, per the California Cannabis Industry Association. This limits addressable markets.

  4. Counterparty Risk: Many cannabis companies have defaulted on debt. In 2023, MedMen filed for bankruptcy with $500 million in debt. Cresco Labs restructured $300 million in debt. If you own bonds or shares of weak operators, you could lose everything.

  5. Black Market Competition: In states with high taxes (e.g., California: 30% combined state+local tax), the black market thrives. The California Department of Tax and Fee Administration estimates 60% of cannabis sales are illicit. This depresses legal sales and margins.

How Can You Analyze a Cannabis Company’s Financial Health?

After 12 years analyzing companies, I use a specific framework for cannabis. Here’s my checklist:

  1. Cash Flow from Operations: This is the most important metric. A company that generates positive cash flow can survive without raising capital. Negative cash flow means they’re burning cash—and will need to dilute shareholders or take on expensive debt. Target: positive cash flow for at least two consecutive quarters.

  2. Debt-to-EBITDA Ratio: Cannabis companies often carry high debt. A ratio below 3x is manageable; above 5x is dangerous. For example, Curaleaf’s ratio is 2.1x; Ayr Wellness is 5.8x. The latter is at risk of default if interest rates stay high.

  3. Gross Margin: This tells you their production efficiency. Top MSOs have 45-50% gross margins. Anything below 30% suggests they’re selling commodity flower with no pricing power. Avoid.

  4. Revenue per Dispensary: For MSOs, this measures operational efficiency. Curaleaf generates $9.3 million per dispensary; Trulieve does $8.5 million. If a company has many dispensaries but low per-store revenue (e.g., $3 million), they’re likely in weak markets or have poor management.

  5. Cash Burn Rate: Calculate their quarterly cash burn (negative cash flow from operations plus capex). Divide by cash on hand. If they have less than 12 months of cash runway, they’re at risk of bankruptcy.

Metric Healthy MSO Warning Sign
Cash Flow from Ops Positive Negative for 4+ quarters
Debt/EBITDA <3x >5x
Gross Margin >45% <30%
Revenue/Dispensary >$7M <$4M
Cash Runway >18 months <12 months

What Is the Future of Cannabis ETFs and Passive Investing?

Cannabis ETFs have been a mixed bag. The AdvisorShares Pure US Cannabis ETF (MSOS) has $1.2 billion in asset](/articles/asset-location-strategy-which-accounts-should-hold-which-inv-1781023338884)s under management but has lost 60% of its value since its 2021 peak. The Global X Cannabis ETF (POTX) is down 75%. However, I believe ETFs are the best way for most investors to gain exposure, because they diversify away single-stock risk.

The top cannabis ETFs as of early 2025:

  • MSOS: Focuses on U.S. MSOs. 0.74% expense ratio. Top holdings: Curaleaf (18%), Trulieve (15%), Green Thumb (12%). Downside: high volatility, but captures the U.S. market.
  • POTX: Global exposure, including Canadian LPs and ancillary companies. 0.50% expense ratio. Top holdings: Tilray (12%), Canopy (10%), Scotts Miracle-Gro (8%). Less volatile but lower growth potential.
  • CNBS: The Amplify Seymour Cannabis ETF. 0.75% expense ratio. More balanced, includes U.S. and Canadian companies.

My Recommendation: For a long-term portfolio, allocate no more than 5% to cannabis ETFs. The sector is still too young and volatile for a core holding. Use MSOS if you believe U.S. federal reform is coming; use POTX if you want global diversification.

Passive Investing Trap: Don’t buy individual cannabis stocks as a “buy and hold forever” strategy. The industry is evolving too fast. I’ve seen companies like Canopy Growth go from $60 to $3. You need to actively monitor positions and be willing to sell when fundamentals deteriorate.

Key Takeaways for Cannabis Investors

  1. Focus on Cash Flow: Ignore hype. Only invest in companies with positive cash flow from operations. The top three MSOs (Curaleaf, Trulieve, Green Thumb) are the safest bets.
  2. Avoid Penny Stocks: 95% of penny weed stocks will go to zero. They’re speculative vehicles with poor financials.
  3. Watch Regulatory Catalysts: Rescheduling to Schedule III and SAFE Banking Act passage could boost stocks 30-50%. But don’t bet on timing—politicians move slowly.
  4. Diversify with ETFs: MSOS or POTX are better than individual stock picking for most investors.
  5. Limit Allocation to 5%: Cannabis is a high-risk sector. Don’t let FOMO drive you to over-allocate.
  6. Monitor Debt Levels: High debt is the #1 killer of cannabis companies. Check debt-to-EBITDA ratios quarterly.

Frequently Asked Questions

Question: Are marijuana stocks a good investment in 2025? Yes, but only with caution. The global legal cannabis market is growing at 23.9% CAGR and will reach $73.6 billion by 2027. However, most cannabis stocks have lost value since 2021. Focus on profitable MSOs like Curaleaf, Trulieve, and Green Thumb, or use ETFs like MSOS. Avoid penny stocks and Canadian LPs with negative cash flow.

Question: What is the best cannabis stock to buy now? Based on financial health, Curaleaf (CURLF) is the strongest, with $1.4 billion revenue, 48% gross margins, and positive cash flow. Trulieve (TCNNF) is a close second with

Tags:
investingstocksportfolio
Ad